Myrexis, Inc. (Formerly Known as Myriad Pharmaceuticals, Inc.) Presents Data on Hsp90 Inhibitor Program at 102nd American Association for Cancer Research Annual Meeting

SALT LAKE CITY, April 5, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it presented four posters on its fully synthetic, orally bioavailable heat shock protein 90 (Hsp90) inhibitor, MPC-3100, at the 102nd annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. MPC-3100 is currently completing Phase 1 clinical studies in patients with refractory cancers.